Current management of sickle cell anemia

Cold Spring Harbor Perspectives in Medicine

Volumn 3, Issue 8, 2013, Pages

  McGann, Patrick T ^a,b   Nero, Alecia C ^c   Ware, Russell E ^a,b  

^a Texas Children's Center for Global Health   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISICKLING AGENT; HYDROXYUREA; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE;

ARTICLE; CEREBROVASCULAR ACCIDENT; CHILD; CLINICAL TRIAL (TOPIC); EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; NEWBORN; NEWBORN SCREENING; PATIENT EDUCATION; SICKLE CELL ANEMIA; TREATMENT OUTCOME;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; EARLY DIAGNOSIS; EVIDENCE-BASED MEDICINE; FOLLOW-UP STUDIES; HUMANS; HYDROXYUREA; INFANT, NEWBORN; NEONATAL SCREENING; PATIENT EDUCATION AS TOPIC; PENICILLINS; PNEUMOCOCCAL VACCINES; STROKE; TREATMENT OUTCOME;

EID: 84881069732     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a011817     Document Type: Article

References (134)

1. Adams R.J, Bramilla D. 2005. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 353: 2769-2778.
2. Adams R.J, Nichols F.T, McKie V.C, McKie K.M, Stephens S, Carl E, Thompson W.O. 1989. Transcranial Doppler: Influence of hematocrit in children with sickle cell anemia without stroke. J Cardiovasc Technol 8: 97-101.
3. Adams R, McKie V, Nichols F, Carl E, Zhang D.L, McKie K, Figueroa R, Litaker M, Thompson W, Hess D. 1992. The use oftranscranial ultrasoundography topredict stroke in sickle cell disease. N Engl J Med 326: 605-610.
4. Adams R.J, McKie V.C, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols F.T, et al. 1998. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 339: 5-11.
5. Ahmad F.A, Macias C.G, Allen J.Y. 2011. The use of incentive spirometry in pediatric patients with sickle cell disease to reduce the incidence of acute chest syndrome. J Pediatr Hematol Oncol 33: 415-420.
6. Al Hajeri A, Serjeant G.R, Fedorowicz Z. 2008. Inhaled nitric oxide for acute chest syndrome in people with sickle cell disease.Cochrane Database Syst Rev 1: CD006957.
7. Ali S.B, Moosang M, King L, Knight-Madden J, Reid M. 2011. Stroke recurrence inchildren with sickle cell disease treated with hydroxyurea following first clinical stroke. Am J Hematol 86: 846-850.
8. Almeida A.M, Henthorn J.S, Davies S.C. 2001. Neonatal screening for haemoglobinopathies: The results of a 10-year programme in an English Health Region. Br J Hem-atol 112: 32-35.
9. Ammann A.J, Addiego J, Wara D.W, Lubin B, Smith W.B, Mentzer W.C. 1977. Polyvalent pneumococcal-polysac-charide immunization of patients with sickle-cell anemia and patients with splenectomy. N Engl J Med 297: 897-900.
10. Ataga K.I. 2009. Novel therapies in sickle cell disease. Hema-tology Am Soc Hematol Educ Program 2006: 54-61.
11. Ataga K.I, Reid M, Ballas S.K, Yasin Z, Bigelow C, James L.S, Smith W.R, Galaceros F, Kutlar A, Hull J.H, et al. 2011. Improvements in haemolysis and indicators of erythro-cyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: A phase III randomized placebo-controlled double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Br J Hematol 153: 92-104.
12. Atweh G.F, Sutton M, Nassif I, Boosalis V, Dover G.J, Wallenstein S, Wright E, McMahon L, Stamatoyan-nopoulos G, Faller DV, et al. 1999. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 93: 1790-1797.
13. Balkaran B, Char G, Morris J.S, Thomas T.W, Serjeant B.E, Serjeant G.R. 1992. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr 120: 360-366.
14. Ballas S.K, Lieff S, Benjamin L.J, Dampler C.D, Heeney M.M, Hoppe C, Johnson C.S, Rogers Z.R, Smith-Whitley K, Wang W.C, et al. 2010. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol 85: 6-13.
15. Bardakdjian-Michau J, Guilloud-Batailie M, Maier-Redel-sperger M, Elion J, Girot R, Feingold J, Galactéros F, Demontalembert M. 2001. Decreased morbidity in homo-zygous sickle cell disease detected at birth. Hemoglobin 26: 211-217.
16. Bellet P.S, Kalinyak K.A, Shukla R, Gelfand M.J, Ruck-nagel D.L. 1995. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med 333: 699-703.
17. Benjamin L.R, Swinson G.I, Nagel R.L. 2000. Sickle cell anemia day hospital: An approach for the management of uncomplicated painful crises. Blood 95: 1130-1136.
18. Bernaudin F, Verlhac S, Arnaud C, Kamdem A, Chevret S, Hau I, Cöic L, Leveillé E, Lemarchand E, Lesprit E, et al. 2011. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood 117: 1130-1140.
19. Bradner J.E, Mak R, Tanguturi S.K, Mazitschek R, Hag-garty S.J, Ross K, Chang C.Y, Bosco J, West N, Morse E, et al. 2010. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci 107: 12617-12622.
20. Brousseau D.C, Owens P.L, Mosso A.L, Panepinto J.A, Stei-ner C.A. 2010. Acute care utilization and rehospitalization for sickle cell disease. JAMA 303: 1288-1294.
21. Castro O, Brambilla D.J, Thorington B, Reindorf C.A, Scott R.B, Gillette P, Vera J.C, Levy P.S. 1994. The acute chest syndrome in sickle cell disease: Incidence and risk factors. Blood 84: 643-649.
22. Charache S. 1990. Fetal hemoglobin, sickling, and sickle cell disease. Adv Pediatr 37: 1-31.
23. Charache S, Scott J.C, Charache P. 1979. "Acute chest syndrome" in adults with sickle cell anemia. Arch Intern Med 139: 67-69.
24. Charache S, Dover G.J, Moore R.D, Eckert S, Ballas S.K, Koshy M, Milner P.F, Orringer E.P, Phillips G Jr, Platt O.S. 1992. Hydroxyurea: Effects on hemoglobin F production in patients with sickle cell anemia. Blood 79: 2555-2565.
25. Charache S, Terrin M.L, Moore R.D, Dover G.J, Barton F.B, Eckert S.V, McMahon R.P, Bonds D.R, and the Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. 1995. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332: 1317-1322.
26. Conley C.L, Weatherall D.J, Richardson S.N, Shepard M.K, Charache S. 1963. Hereditary persistence of fetal hemoglobin: A study of 79 affected persons in 15 Negro families in Baltimore. Blood 21: 261-281.
27. Creusot F, Acs G, Christman J.K. 1982. Inhibition of DNA methyltransferase and induction of Friend erythroleuke-mia cell differentiation by 5-azacytidine and 5-aza2'-de-oxycytidine. J Biol Chem 257: 2041-2048.
28. Dampier C, Ely E, Eggleston B, Brodecki D, O'Neal P. 2004. Physical and cognitive-behavioral activities used in the home management of sickle pain: A daily diary study in children and adolescents. Pediatr Blood Cancer 43: 674-678.
29. DeBaun M.R, Armstrong F.D, McKinstry R.C, Ware R.E, Vichinsky E, Kirkham F.J. 2012. Silent cerebral infarcts: A review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood 119: 4587-4596.
30. Deodhar H.A, Marshall R.J, Barnes J.N. 1993. Increased risk of sepsis after splenectomy. BMJ 307: 1408-1409.
31. DeSimone J, Koshy M, Dorn L, Lavelle D, Bressler L, Molokie R, Talischy N. 2002. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 99: 3905-3908.
32. Diggs L.W. 1973. Anatomic lesions in sickle cell disease. In Sickle cell disease: Diagnosis, management, education, and research (ed. Abramson H, et al.), pp. 189-229. Mosby, St. Louis.
33. Emond A.M, Collis R, Darvill D, Higgs D.R, Maude G.H, Serjeant G.R. 1985. Acute splenic sequestration in homo-zygous sickle cell disease: Natural history and management. J Pediatr 107: 201-206.
34. Enninful-Eghan H, Moore R.H, Ichord R, Smith-Whitley K, Kwiatkowski J.L. 2010. Transcranial Doppler ultrasonog-raphy and prophylactic transfusion program is effective in preventing overt stroke in children with sickle cell disease. J Pediatr 157: 479-484.
35. Falletta J.M, Woods G.M, Verter J.I, Buchanan G.R, Pege-low C.H, Iyer R.V, Miller S.T, Holbrook C.T, Kinney T.R, Vichinsky E, et al. 1995. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. J Pediatr 127: 685-690.
36. Gaston M.H, Verter J.I, Woods G, Pegelow C, Kelleher J, Pres-bury G, Zarkowsky H, Vichinsky E, Iyer R, Lobel J.S, et al. 1986. Prophylaxis with oral penicillin in children with sickle cell anemia. N Engl J Med 314: 1593-1599.
37. Gill F.M, Sleeper L.A, Weiner S.J, Brown A.K, Bellevue R, Grover R, Pegelow C.H, Vichinsky E. 1995. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood 86: 776-783.
38. Gladwin M.T, Schechter A.N, Shelhamer J.H, Ognibene F.P. 1999. The acute chest syndrome in sickle cell disease: Possible role of nitric oxide in its pathophysiology and treatment. Am J Resp Crit Care Med 159: 1368-1376.
39. Gladwin M.T, Sachdev V, Jison M.L, Shizukuda Y, Plehn J.F, Minter K, Brown B, Coles W.A, Nichols J.S, Ernst I, et al. 2004. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350: 886-895.
40. Griffin T.C, McIntire D, Buchanan GR. 1994. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease.NEnglJ Med 330: 733-737.
41. Grosse S.D, Olney R.S, Baily M.A. 2005. The cost effectiveness of universal versus selective newborn screening for sickle cell disease in the US and the UK: A critique. Appl Health Econ Health Policy 4: 239-247.
42. Halasa N.B, Shankar S.M, Talbot T.R, Arbogast P.G, Mit-chel E.F, Wang W.C, Schaffner W, Craig A.S, Griffin M.R. 2007. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 44: 1428-1433.
43. Hankins J, Jeng M, Harris S, Li C.S, Liu T, Wang W. 2005. Chronic transfusion therapy for children with sickle cell disease and recurrent acute chest syndrome. J Pediatr Hematol Oncol 27: 158-161.
44. Hankins J.S, Ware R.E, Rogers Z.R, Wynn L.W, Lane P.A, Scott J.P, Wang W.C. 2005. Long-term hydroxyurea therapy for infants with sickle cell anemia: The HUSOFT extension study. Blood 106: 2269-2275.
45. Hankins J.S, Helton K.J, McCarville M.B, Li C.S, Wang W.C., Ware R.E. 2008. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxy-urea. Pediatr Blood Cancer 50: 293-297.
46. Harmatz P, Butensky E, Quirolo K, Williams R, Ferrell L, Moyer T, Golden D, Neumayr L, Vichinsky E. 2000. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 96: 76-79.
47. Heeney M.M, Ware R.E. 2008. Hydroxyurea for children with sickle cell disease. Pediatr Clin N Am 55: 483-501.
48. Hines P, Dover G.J, Resar L.M. 2008. Pulsed-dosing with oral sodium phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia. Pediatr Blood Cancer 50: 357-359.
49. Hulbert M.L, Scothorn D.J, Panepinto J.A, Scott J.P, Buchanan G.R, Sarnaik S, Fallon R, Chu J.Y, Wang W, Casella J.F, et al. 2006. Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: A retrospective cohort study of 137 children with sickle cell anemia. J Pediatr 149: 710-712.
50. Hulbert M.L, McKinstry R.C, Lacey J.L, Moran C.J, Pane-pinto J.A, Thompson A.A, Sarnaik S.A, Woods G.M, Casella J.F, Inusa B, et al. 2011. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood 117: 772-779.
51. Jacob E, Hockenberry M, Mueller B.U. 2008. Effects of patient controlled analgesia hydromorphone during acute painful episodes in adolescents with sickle cell disease: A pilot study. J Pain Manag 1: 173-178.
52. Kinney T.R, Ware R.E, Schultz W.H, Filston H.C. 1990. Long-term management of splenic sequestration in children with sickle cell disease. J Pediatr 117: 194-199.
53. Kinney T.R, Helms R.W, O'Branski E.E, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt O.S, et al. 1999. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 94: 1550-1554.
54. Kleinman S.H, Hurvitz C.G, Goldfinger D. 1984. Use of erythrocytapheresis in the treatment of patients with sickle cell anemia. J Clin Apher 2: 170-176.
55. Knight-Madden J.A, Hambleton I.R. 2003. Inhaled broncho-dilators for acute chest syndrome in people with sickle cell disease. Cochrane Database Syst Rev 3: CD003733.
56. Knight-Madden J.M, Forrester T.S, Lewis N.A, Greenough A. 2005. Asthma in children with sickle cell disease and its association with acute chest syndrome. Thorax 60: 206-210.
57. Kwiatkowski J.L, Yim Eunsil, Miller S, Adams R.J. 2011. Effect of transfusion therapy on transcranial doppler ultraso-nography velocities in children with sickle cell disease. Pediatr Blood Cancer 56: 777-782.
58. Lane P.A, Buchanan G.R, Hutter J.J, Austin R.F, Britton H.A, Rogers Z.R, Eckman J.R, DeBaun M.R, Wang W.C, Matthew P, et al. 2001. Sickle cell disease in children and adolescents: Diagnosis, guidelines for comprehensive care and care paths and protocols for management of acute and chronic complications. Health Resources and Services Administration, Department of Health and Human Services, http://www.scinfo.org/protchild-index.htm.
59. Lanzkowsky P, Shende A, Karayalcin G, Kim Y.J., Aballi A.J. 1978. Partial exchange transfusion in sickle cell anemia: Use in children with serious complications. Am J Dis Child 132: 1206-1208.
60. Lee M.T, Piomelli S, Granger S, Miller S.T, Harkness S, Brambilla D.J, Adams R.J. 2006. Stroke prevention trial in sickle cell anemia (STOP): Extended follow-up and final results. Blood 108: 847-852.
61. Lottenberg R, Hassell K.L. 2005. An evidence-based approach to the treatment of adults with sickle cell disease. Hematol Am Soc Hematol Educ Program 2006: 58-65.
62. Lowenthal E.A, Wells A, Emanuel P.D, Player R, Prchal J.T. 1996. Sickle cell acute chest syndrome associated with parvovirus B19 infection: Case series and review. Am J Hematol 51: 207-213.
63. Lusher J.M, Haghighat H, Khalifa A.S. 1976. A prophylactic transfusion program for children with sickle cell anemia complicated by CNS infarction. Am J Hematol 1: 265-273.
64. Martí-Carvajal A.J, Conterno L.O, Knight-Madden J.M. 2007. Antibiotics for treating acute chest syndrome in people with sickle cell disease. Cochrane Database Syst Rev 2: 1-14.
65. McCaffrey P.G, Newsome D.A, Fibach E, Yoshida M, Su M.S. 1997.Induction of g-globin by histone decetylase inhib itors. Blood 90: 2075-2083.
66. McCarville M.B, Goodin G.S, Fortner G, Chin-Shang L, Smeltzer M.P, Adams R, Wang W. 2008. Evaluation of a comprehensive transcranial doppler screening program for children with sickle cell anemia. Pediatr Blood Cancer 50: 818-821.
67. McGann P.T, Ware R.E. 2011. Hydroxyurea for sickle cell anemia: What have we learned and what questions still remain? Curr Opinion Hematol 18: 158-165.
68. Miller S.T. 2011. How I treat acute chest syndrome in children with sickle cell disease. Blood 117: 5297-5305.
69. Miller S.T, Hammerschlag M.R, Chirgwin K, Rao S.P, Roblin P, Gelling M, Stilerman T, Schachter J, Cassell G. 1991. Role of Chlamydia pneumoniae in acute chest syndrome of sickle cell disease. J Pediatr 118: 30-33.
70. Miller S.T, Wright E, Abboud M, Berman B, Files B, Scher C.D, Styles L, Adams R.J. 2001a. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP)in sickle-cell anemia. J Pediatr 139: 785-789.
71. Miller S.T, Macklin E.A, Pegelow C.H, Kinney T., Sleeper L.A, Bello J.A, DeWitt L.D, Gallagher D.M, Guarini L, Mo-ser F.G, et al. 2001b. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: A report from the Cooperative Study of Sickle Cell Disease. J Pe-diatr 139: 385-390.
72. Neumayr L, Lennette E, Kelly D, Earles A, Embury S, Groncy P, Grossi M, Grover R, McMahon L, Swerdlow P, et al. 2003. Mycoplasma disease and acute chest syndrome in sickle cell disease. Pediatrics 112: 87-95.
73. O'Brien S.H, Fan L, Kelleher K.J. 2010. Inpatient use of laxatives during opioid administration inchildrenwith sickle cell disease. Pediatr Blood Cancer 54: 559-562.
74. Ohene-Frempong K, Weiner S.J., Sleeper L.A, Miller S.T, Embury S, Moohr J.W, Wethers D.L, Pegelow C.H, Gill F.M. 1998.Cerebrovascular accidents in sickle cell disease: Rates and risk factors. Blood 91: 288-294.
75. Overturf G.D, Powars D, Barraf L.J. 1977. Bacterial meningitis and septicemia in sickle cell disease. Am J Dis Child 131: 784-787.
76. Pearson H.A. 1977. Sickle cell anemia and severe infections due to encapsulated bacteria. J Infect Dis 136: S25-S30.
77. Pearson H.A, Spencer R.P, Cornelius E.A. 1969. Functional asplenia in sickle-cell anemia. N Engl J Med 281: 923- 926.
78. Pegelow C.H, Adams R.J, McKie V, Abboud M, Berman B, Miller S.T, Olivieri N, Vichinsky E, Wang W, Brambilla D. 1995. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 126: 896-899.
79. Pegelow C.H, Macklin E.A, Moser F.G, Wang W.C, Bello J.A, Miller S.T, Vichinsky E.P, DeBaun M.R, Guarini L, Zimmerman R.A, et al. 2001. Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood 99: 3014-3018.
80. Platt O.S. 2006. Prevention and management of stroke in sickle cell anemia. Hematology Am Soc Hematol Educ Program 2006: 54-57.
81. Platt O.S, Orkin S.H, Dover G, Beardsley G.P, Miller B, Nathan D.G. 1984. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 74: 652-656.
82. Platt O.S, Thorington B.D, Brambilla D.J, Milner P.F, Rosse W.F, Vichinsky E, Kinney T.R. 1991. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 325: 11-16.
83. Platt O.S, Brambilla D.J, Rosse W.F, Milner P.F, Castro O, Steinberg M.H, Klug P.P. 1994. Mortality in sickle cell disease-Life expectancy and risk factors for early death. N Engl J Med 330: 1639-1644.
84. Powars D.R. 1975. Natural history of sickle cell disease-The first ten years. Semin Hematol 12: 267-285.
85. Powars D, Wilson B, Imbus C, Pegelow C, Allen J. 1978. The natural history of stroke in sickle cell disease. Am J Med 65: 461-71.
86. Powars D, Overturf G, Weiss J, Lee S, Chan L. 1981. Pneu-mococcal septicemia in children with sickle cell anemia. Changing trend of survival. JAMA 245: 1839-1842.
87. Powars D.R, Chan L.S, Hiti A, Ramicone E, Johnson C. 2005. Outcome of sickle cell anemia: A 4-decade observational study of 1056 patients. Medicine 84: 363-376.
88. Powell R.W, Levine G.L, Yang Y.M, Mankad V.N. 1992. Acute splenic sequestration crisis in sickle cell disease: Early detection and treatment. J Pediatr Surg 27: 215-219.
89. Quinn C.T, Rogers Z.R, McCavit T.L, Buchanan G.R. 2010. Improved survivalof children and adolescents with sickle cell disease. Blood 115: 3447-3452.
90. Raphael J.L, Kamdar A, Wang T, Liu H, Mahoney D.H, Mueller B.U. 2008. Day hospital versus inpatient management of uncomplicated vaso-occlusive crises in children with sickle cell disease. Pediatr Blood Cancer 51: 398-401.
91. Redwood A.M, Williams E.M, Desal P, Serjeant G.R. 1976. Climate and painful crisis of sickle-cell disease in Jamaica. Br Med J 1: 66.
92. Rees D.C, Olujohungbe A.D, Parker N.E, Stephens A.D, Telfer P, Wright J. 2003. Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Hem-atol 120: 744-752.
93. Resar L.M, Oski F.A. 1991. Cold water exposure and vaso-occlusive crises in sickle cell anemia. J Pediatr 118: 407.
94. Rice H.E, Oldham K.T, Hillery C.A, Skinner M.A, O'Hara S.M, Ware R.E. 2003. Clinical and hematologic benefits of partial splenectomy for congenital hemolytic anemias in children. Ann Surg 237: 281-288.
95. Rogers D.W, Clarke J.M, Cupidore L, Ramlal A.M, Sparke B.R, Serjeant G.R. 1978. Early deaths inJamaican children with sickle cell disease. Br Med J 1: 1515-1516.
96. Rosse W.F, Gallagher D, Kinney T.R, Castro O, Dosik H, Moohr J, Wang W, Levy P.S. 1990. Transfusion and al-loimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 76: 1431-1437.
97. Saunthararajah Y, Hillery C.A, Lavelle D, Molokie R, Dorn L, Bressler L, Gavazova S, Chen Y.H, Hoffman R, DeSimone J. 2003. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hemato-poietic differentiation in patients with sickle cell disease. Blood 102: 3865-3870.
98. Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gow-hari M, Vara S,Lavelle D, DeSimone J. 2008. Clinicaleffectiveness of decitabine in severe sickle cell disease. Br J Haematol 141: 126-129.
99. Schatz J, Brown R.T, Pascual J.M, Hsu L, DeBaun M.R. 2001. Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology 56: 1109-1111.
100. Scothorn D.J, Price C, Schwartz D, Terrill C, Buchanan G.R, Shurney W, Sarniak I, Fallon R, Chu J.Y, Pegelow C.H, etal. 2002. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr 140: 348.
101. Serjeant G.R. 1995. Natural history and determinants of clinical severity of sickle cell disease. Curr Opin Hematol 2: 103-108.
102. Smith W.R, Penberthy L.T, Bovbjerg V.E, McClish D.K, Roberts J.D, Dahman B, Aisiku I.P, Levenson J.L, Roseff SD. 2008. Daily assessment of pain in adults with sickle cell disease. Ann Int Med 148: 94-101.
103. Smith-Whitley K, Thompson A.A. 2012. Indications and complications of transfusions in sickle cell disease. Pe-diatr Blood Cancer 59: 358-364.
104. Solomon L.R. 2008. Treatment and preventionof pain due to vaso-occlusive crises in adults with sickle cell disease: An educational void. Blood 111: 997-1003.
105. Steinberg M.H, Barton F, Castro O, Pegelow C.H, Ballas S.K, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, et al. 2003. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. J Am Med Assoc 289: 1645-1651.
106. Steinberg M.H, McCarthy W.F, Castro O, Ballas S.K, Armstrong F.D, Smith W, Ataga K, Swerdlow P, Kut-lar A, DeCastro L, et al. 2010. The risks and benefits of long-term useof hydroxyureainsickle cell anemia:A17.5 year follow-up. Am J Hematol 85: 403-408.
107. Sträter R, Becker S, von Eckardstein A, Heinecke A, Gutsche S, Junker R, Kurnik K, Schobess R, Nowak-Göttl U. 2002. Prospective assessment of risk factors for recurrent stroke during childhood-a 5-year follow-up study. Lancet 360: 1540-1545.
108. Swerdlow P.S. 2006. Red cell exchange in sickle cell disease. Am Soc Hematol Educ Program 2006: 48-53.
109. Telfer P, Coen P, Chakravorty S, Wilkey O, Evans J, Newell H, Smalling B, Amos R, Stephens A, Rogers D, et al. 2007. Clinical outcomes in children with sickle cell disease living in England: A neonatal cohort in East London. Hae-matologica 92: 905-912.
110. Thompson R.J, Gustafson K.E, Bonner M.J, Ware R.E. 2002. Neurocognitive development of young children with sickle cell disease through three years of age. J Pediatr Psychol 27: 235-244.
111. Thornburg C.D, Dixon N, Burgett S, Mortier N.A, Schultz W.H, Zimmerman S.A, Bonner M, Hardy K.K, Calatroni A, Ware R.E. 2009. A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer 52: 609-615.
112. Topley J.M, Rogers D.W, Stevens M.C.G, Serjeant G.R. 1981. Acute splenic sequestration and hypersplenism first five years inhomozygous sickle cell disease. Arch Dis Child 56: 765-769.
113. Vanbeers E.J, van Tuijn C.F, Nieuwkerk P.T, Friederich P.W, Vranken J.H, Biemond B.J. 2007. Patient-controlled analgesiaversus continuous infusion ofmorphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial. Am J Hematol 82: 955-960.
114. Velasquez M.P, Mariscalco M.M, Goldstein S.L, Airewele G.E. 2009. Erythrocytapheresis in children with sickle cell disease and acute chest syndrome. Pediatr Blood Cancer 53: 1060-1063.
115. Vichinsky E, Hurst D, Earles A, Kleman K, Lubin B. 1988. Newborn screening for sickle cell disease: Effect on mortality. Pediatrics 81: 749-755.
116. Vichinsky E, Williams R, Das M, Earles A.N, Lewis N, Adler A, McQuitty J. 1994. Pulmonary fat embolism: A distinct cause of severe acute chest syndrome in sickle cell anemia. Blood 83: 3107-3112.
117. Vichinsky E.P, Neumayr L.D, Earles A.N, Williams R, Len-nette E.T, Dean D, Nickerson B, Orringer E, McKie V, Bellevue R, et al. 2000. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 342: 1855-1865.
118. Voskaridou E, Christoulas D, Bilalis A, Plata E, Varva-giannis K, Stamatopoulos G, Sinopoulou K, Bala-ssopoulou A, Loukopoulos D, Terpos E. 2010. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: Results of a 17-year, single-center trial (LaSHS). Blood 115: 2354-2363.
119. Wang W.C, Kovnar E.H, Tonkin I.L, Mulhern R.K, Lang-ston J.W, Day S.W, Schell M.J, Wilimas J.A. 1991. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr 118: 377-382.
120. Wang W.C, Wynn L.W, Rogers Z.R,Scott J.P,Lane P.A,Ware R.E. 2001. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr 139: 790-796.
121. Wang W.C, Ware R.E, Miller S.T, Iyer R.V, Casella J.F, Minniti C.P, Rana S, Thornburg C.D, Rogers Z.R, Kalpatthi R.V, et al. 2011. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet 377: 1663-1672.
122. Ware R.E. 2010. Acute vaso-occlusion in sickle cell anemia. In European Haematology Association Educational Handbook. Hague, The Netherlands.
123. Ware R.E. 2010. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 115: 5300-5311.
124. Ware R.E, Zimmerman S.A, Schultz W.H. 1999. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 94: 3022-3026.
125. Ware R.E, Zimmerman S.A, Sylvestre P.B, Mortier N.A, Davis J.S, Treem W.R, Schultz W.H. 2004. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hy-droxyurea and phlebotomy. J Pediatr 145: 346-352.
126. Ware R.E, Despotovic J.M, Mortier N.A, Flanagan J.M, He J, Smeltzer M.P, Kimble A.C, Aygun B, Wu S, Howard T, et al. 2011. Pharmacokinetics, pharmacodynamics, and phar-macogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood 118: 4985-4991.
127. Ware R.E, Helms R.W, for the SWiTCH Investigators. 2012. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood 119: 3925-3932.
128. Wayne A.S, Schoenike S.E, Pegelow C.H. 2000. Financial analysis of chronic transfusion for stroke prevention in sickle cell disease. Blood 96: 2369-2372.
129. Williams T.N, Uyoga S, Macharia A, Ndila C, McAuley C.F, Opi D.H, Mwarumba S, Makani J, Komba A, Ndiritu M.N, et al. 2009. Bacteraemia in Kenyan children with sickle-cell anaemia: A retrospective cohort and case-control study. Lancet 374: 1364-1370.
130. Winkelstein J.A, Drachman R.H. 1968. Deficiency of pneu-mococcal serum opsonizing activity in sickle cell disease. N Engl J Med 279: 459-466.
131. Yazdanbakhsh K, Ware R.E, Noizat-Pirenne F. 2012. Red blood cell alloimmunization in sickle cell disease: Path-ophysiology, risk factors, and transfusion management. Blood 120: 528-537.
132. Yoong W.C, Tuck S.M. 2002. Menstrual pattern in women with sickle cell anaemia and its association with sickling crises. J Obstet Gynaecol 22: 399-401.
133. Zimmerman S.A, Schultz W.H, Davis J.S, Pickens C.V., Mortier N.A, Howard T.A, Ware R.E. 2004. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 103: 2039-2045.
134. Zimmerman S.A, Schultz W.H, Burgett S, Mortier N.A, Ware R.E. 2007. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 110: 1043-1047.